Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months

Autoři	GRYGÁRKOVÁ I. KOLEK V. SKŘIČKOVÁ Jana PEŠEK M. ZATLOUKAL P. SALAJKA F. ROUBEC J. SIXTOVÁ D. KOUBKOVÁ L. HEJDUK Karel
Rok publikování	2012
Druh	Konferenční abstrakty
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Přiložené soubory	Skrickovlung_cancer_.pdf
Popis	Targeted biological therapy with inhibitors of tyrosine kinases is one of the therapeutic modality therapies of advanced stage non-small cell lung cancer (NSCLC). These drugs block activation cascade of epidermal growth factor receptor (EGFR). The sensitivity of tumor cells to tyrosine kinase inhibitors increases the “activating” mutations of tyrosine kinase domain and, especially, deletion in exon 19 or point mutation in exon 21.